Aldevron News: genprex

Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies

Austin, Texas, Cambridge, Mass. and Fargo, N.D. – September 26, 2018 – Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.

Read More